You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameHalothane
Accession NumberDB01159  (APRD00598, EXPT01754, DB02330)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178)
Structure
Thumb
Synonyms
1-Bromo-1-chloro-2,2,2-trifluoroethane
1,1,1-Trifluoro-2-bromo-2-chloroethane
1,1,1-Trifluoro-2-chloro-2-bromoethane
2-Bromo-2-Chloro-1,1,1-Trifluoroethane
2,2,2-Trifluoro-1-chloro-1-bromoethane
Bromochlorotrifluoroethane
Fluothane
Ftorotan
Halotano
Halothane
Halothanum
Narcotane
Phthorothanum
Rhodialothan
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fluothane AnestheticliquidinhalationAyerst Laboratories1958-12-311996-09-10Canada
Fluothane Liq Inh 1000mg/gmliquid1 ginhalationWyeth Ayerst Canada Inc.1994-12-311997-08-14Canada
Halothanesolution99.99 %inhalationBimeda Mtc Animal Health Inc1975-12-31Not applicableCanada
Halothane Liq 99.9%liquid99.9 %inhalationHalocarbon Laboratories, A Division Of Halocarbon Products Corp.1971-12-312010-06-14Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
FluothaneAyerst
HalotanJugoremedija
NarcotanZentiva
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIUQT9G45D1P
CAS number151-67-7
WeightAverage: 197.382
Monoisotopic: 195.890225001
Chemical FormulaC2HBrClF3
InChI KeyInChIKey=BCQZXOMGPXTTIC-UHFFFAOYSA-N
InChI
InChI=1S/C2HBrClF3/c3-1(4)2(5,6)7/h1H
IUPAC Name
2-bromo-2-chloro-1,1,1-trifluoroethane
SMILES
FC(F)(F)C(Cl)Br
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as organofluorides. These are compounds containing a chemical bond between a carbon atom and a fluorine atom.
KingdomOrganic compounds
Super ClassOrganohalogen compounds
ClassOrganofluorides
Sub ClassNot Available
Direct ParentOrganofluorides
Alternative Parents
Substituents
  • Hydrocarbon derivative
  • Organofluoride
  • Organochloride
  • Organobromide
  • Alkyl halide
  • Alkyl fluoride
  • Alkyl chloride
  • Alkyl bromide
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the induction and maintenance of general anesthesia
PharmacodynamicsHalothane is a general inhalation anesthetic used for induction and maintenance of general anesthesia. It reduces the blood pressure and frequently decreases the pulse rate and depresses respiration. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential.
Mechanism of actionHalothane causes general anaethesia due to its actions on multiple ion channels, which ultimately depresses nerve conduction, breathing, cardiac contractility. Its immobilizing effects have been attributed to its binding to potassium channels in cholinergic neurons. Halothane's effect are also likely due to binding to NMDA and calcium channels, causing hyperpolarization.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Halothane is metabolized in the liver, primarily by CYP2E1, and to a lesser extent by CYP3A4 and CYP2A6.

SubstrateEnzymesProduct
Halothane
bromideDetails
Halothane
trifluoroacetic acidDetails
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityToxic effects of halothane include malignant hyperthermia and hepatitis.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9895
Caco-2 permeable+0.6141
P-glycoprotein substrateNon-substrate0.9007
P-glycoprotein inhibitor INon-inhibitor0.9628
P-glycoprotein inhibitor IINon-inhibitor0.945
Renal organic cation transporterNon-inhibitor0.9183
CYP450 2C9 substrateNon-substrate0.8374
CYP450 2D6 substrateSubstrate0.8031
CYP450 3A4 substrateNon-substrate0.7086
CYP450 1A2 substrateNon-inhibitor0.6027
CYP450 2C9 inhibitorNon-inhibitor0.7607
CYP450 2D6 inhibitorNon-inhibitor0.943
CYP450 2C19 inhibitorNon-inhibitor0.6841
CYP450 3A4 inhibitorNon-inhibitor0.9545
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8808
Ames testNon AMES toxic0.9132
CarcinogenicityCarcinogens 0.711
BiodegradationNot ready biodegradable0.9741
Rat acute toxicity1.7199 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9686
hERG inhibition (predictor II)Non-inhibitor0.9034
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Liquidinhalation
Liquidinhalation1 g
Solutioninhalation99.99 %
Liquidinhalation99.9 %
Prices
Unit descriptionCostUnit
Halothane liquid0.24USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point50-50.5U.S. Patents 2,849,502, 2,921,098, 2,959,624, 3,082,263.
boiling point50.2 °CPhysProp
water solubility4070 mg/L (at 25 °C)HORVATH,AL ET AL. (1999)
logP2.30HANSCH,C ET AL. (1995)
logS-1.71ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility3.81 mg/mLALOGPS
logP2.5ALOGPS
logP2.12ChemAxon
logS-1.7ALOGPS
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity24.63 m3·mol-1ChemAxon
Polarizability9.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.57 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-014j-2900000000-e961932e23eafc2cc0a5View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
References
Synthesis Reference

U.S. Patents 2,849,502, 2,921,098, 2,959,624, 3,082,263.

General References
  1. Bovill JG: Inhalation anaesthesia: from diethyl ether to xenon. Handb Exp Pharmacol. 2008;(182):121-42. doi: 10.1007/978-3-540-74806-9_6. [PubMed:18175089 ]
External Links
ATC CodesN01AB01
AHFS Codes
  • 28:04.00
PDB Entries
FDA labelNot Available
MSDSDownload (55.2 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Halothane is combined with 7-Nitroindazole.
AbirateroneThe metabolism of Halothane can be decreased when combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Halothane is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Halothane is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Halothane is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Halothane is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Halothane is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Halothane.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Halothane is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Halothane.
AmiodaroneThe metabolism of Halothane can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Halothane is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Halothane is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Halothane is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Halothane is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Halothane is combined with Amperozide.
AprepitantThe serum concentration of Halothane can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Halothane is combined with Aripiprazole.
ArtemetherThe metabolism of Halothane can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Halothane is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Halothane is combined with Asenapine.
AtazanavirThe metabolism of Halothane can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Halothane can be decreased when combined with Atomoxetine.
Atracurium besylateHalothane may increase the neuromuscular blocking activities of Atracurium besylate.
AzaperoneThe risk or severity of adverse effects can be increased when Halothane is combined with Azaperone.
AzelastineHalothane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Halothane.
BaclofenThe risk or severity of adverse effects can be increased when Halothane is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Halothane is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Halothane.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Halothane is combined with Benzyl alcohol.
BetaxololThe metabolism of Halothane can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Halothane can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Halothane can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Halothane can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Halothane can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Halothane is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Halothane.
BrimonidineThe risk or severity of adverse effects can be increased when Halothane is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Halothane is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Halothane is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Halothane is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Halothane.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Halothane.
BupropionThe metabolism of Halothane can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Halothane.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Halothane.
ButacaineThe risk or severity of adverse effects can be increased when Halothane is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Halothane is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Halothane is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Halothane is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Halothane.
CapecitabineThe metabolism of Halothane can be decreased when combined with Capecitabine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Halothane.
CarbinoxamineThe risk or severity of adverse effects can be increased when Halothane is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Halothane is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Halothane is combined with Carisoprodol.
CelecoxibThe metabolism of Halothane can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Halothane can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Halothane is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Halothane is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Halothane.
ChlormezanoneThe risk or severity of adverse effects can be increased when Halothane is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Halothane is combined with Chloroprocaine.
ChloroquineThe metabolism of Halothane can be decreased when combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Halothane is combined with Chlorphenamine.
ChlorpromazineThe metabolism of Halothane can be decreased when combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Halothane is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Halothane is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Halothane is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Halothane can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Halothane can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Halothane can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Halothane.
CitalopramThe risk or severity of adverse effects can be increased when Halothane is combined with Citalopram.
CitalopramThe metabolism of Halothane can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Halothane can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Halothane can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Halothane is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Halothane is combined with Clidinium.
ClobazamThe metabolism of Halothane can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Halothane is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Halothane is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Halothane is combined with Clomipramine.
ClomipramineThe metabolism of Halothane can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Halothane is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Halothane is combined with Clonidine.
ClopidogrelThe metabolism of Halothane can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Halothane.
ClotrimazoleThe metabolism of Halothane can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Halothane can be decreased when combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Halothane is combined with Clozapine.
CobicistatThe serum concentration of Halothane can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Halothane.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Halothane.
ConivaptanThe serum concentration of Halothane can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Halothane can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Halothane is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Halothane.
CyclosporineThe metabolism of Halothane can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Halothane is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Halothane can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Halothane can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Halothane is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Halothane.
DapoxetineThe risk or severity of adverse effects can be increased when Halothane is combined with Dapoxetine.
DarifenacinThe metabolism of Halothane can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Halothane can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Halothane can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Halothane can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Halothane can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Halothane is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Halothane is combined with Desflurane.
DesipramineThe metabolism of Halothane can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Halothane is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Halothane is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Halothane is combined with Detomidine.
DexamethasoneThe serum concentration of Halothane can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Halothane is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Halothane.
DextromoramideThe risk or severity of adverse effects can be increased when Halothane is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Halothane.
DezocineThe risk or severity of adverse effects can be increased when Halothane is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Halothane.
DifenoxinThe risk or severity of adverse effects can be increased when Halothane is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Halothane is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Halothane can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Halothane is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Halothane is combined with Dihydromorphine.
DiltiazemThe metabolism of Halothane can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Halothane is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Halothane can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Halothane is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Halothane.
DisulfiramThe metabolism of Halothane can be decreased when combined with Disulfiram.
DopamineHalothane may increase the arrhythmogenic activities of Dopamine.
DoramectinThe risk or severity of adverse effects can be increased when Halothane is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Halothane is combined with Doxepin.
DoxorubicinThe metabolism of Halothane can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Halothane can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Halothane.
DoxylamineThe risk or severity of adverse effects can be increased when Halothane is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Halothane is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Halothane.
DronedaroneThe metabolism of Halothane can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Halothane.
DrotebanolThe risk or severity of adverse effects can be increased when Halothane is combined with Drotebanol.
DuloxetineThe metabolism of Halothane can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Halothane.
EcgonineThe risk or severity of adverse effects can be increased when Halothane is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Halothane is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Halothane can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Halothane is combined with Efavirenz.
EliglustatThe metabolism of Halothane can be decreased when combined with Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Halothane.
EntacaponeThe risk or severity of adverse effects can be increased when Halothane is combined with Entacapone.
EnzalutamideThe serum concentration of Halothane can be decreased when it is combined with Enzalutamide.
EphedraEphedra may increase the arrhythmogenic activities of Halothane.
EphedrineEphedrine may increase the arrhythmogenic activities of Halothane.
EpinephrineHalothane may increase the arrhythmogenic activities of Epinephrine.
ErythromycinThe metabolism of Halothane can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Halothane is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Halothane can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Halothane is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Halothane.
EthanolHalothane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Halothane.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Halothane.
EthosuximideThe risk or severity of adverse effects can be increased when Halothane is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Halothane is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Halothane is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Halothane is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Halothane is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Halothane is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Halothane is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Halothane is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Halothane.
EtoperidoneThe risk or severity of adverse effects can be increased when Halothane is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Halothane is combined with Etorphine.
EtravirineThe serum concentration of Halothane can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Halothane is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Halothane is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Halothane is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Halothane is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Halothane.
FexofenadineThe risk or severity of adverse effects can be increased when Halothane is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Halothane is combined with Flibanserin.
FloxuridineThe metabolism of Halothane can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Halothane can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Halothane is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Halothane is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Halothane is combined with Flunitrazepam.
FluorouracilThe metabolism of Halothane can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Halothane is combined with Fluoxetine.
FluoxetineThe metabolism of Halothane can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Halothane.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Halothane.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Halothane.
FluspirileneThe risk or severity of adverse effects can be increased when Halothane is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Halothane is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Halothane can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Halothane is combined with Fluvoxamine.
FluvoxamineThe metabolism of Halothane can be decreased when combined with Fluvoxamine.
FormoterolHalothane may increase the arrhythmogenic activities of Formoterol.
FosamprenavirThe metabolism of Halothane can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Halothane can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Halothane.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Halothane.
FospropofolThe risk or severity of adverse effects can be increased when Halothane is combined with Fospropofol.
Fusidic AcidThe serum concentration of Halothane can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Halothane.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Halothane is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Halothane is combined with Gamma Hydroxybutyric Acid.
GemfibrozilThe metabolism of Halothane can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Halothane is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Halothane is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Halothane.
HaloperidolThe metabolism of Halothane can be decreased when combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Halothane is combined with Haloperidol.
HeroinThe risk or severity of adverse effects can be increased when Halothane is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Halothane is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Halothane.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Halothane.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Halothane.
HydroxyzineThe risk or severity of adverse effects can be increased when Halothane is combined with Hydroxyzine.
IdelalisibThe serum concentration of Halothane can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Halothane is combined with Iloperidone.
ImatinibThe metabolism of Halothane can be decreased when combined with Imatinib.
ImipramineThe metabolism of Halothane can be decreased when combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Halothane is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Halothane is combined with Indalpine.
IndinavirThe metabolism of Halothane can be decreased when combined with Indinavir.
IrbesartanThe metabolism of Halothane can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Halothane can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Halothane.
IsoniazidThe metabolism of Halothane can be decreased when combined with Isoniazid.
IsoprenalineHalothane may increase the arrhythmogenic activities of Isoprenaline.
IsradipineThe metabolism of Halothane can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Halothane can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Halothane can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Halothane is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Halothane is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Halothane is combined with Ketobemidone.
KetoconazoleThe metabolism of Halothane can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Halothane is combined with Lamotrigine.
LeflunomideThe metabolism of Halothane can be decreased when combined with Leflunomide.
LevetiracetamThe risk or severity of adverse effects can be increased when Halothane is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Halothane.
LevocabastineThe risk or severity of adverse effects can be increased when Halothane is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Halothane is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Halothane is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Halothane is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Halothane is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Halothane.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Halothane.
LithiumThe risk or severity of adverse effects can be increased when Halothane is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Halothane is combined with Lofentanil.
LopinavirThe metabolism of Halothane can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Halothane is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Halothane.
LorcaserinThe metabolism of Halothane can be decreased when combined with Lorcaserin.
LosartanThe metabolism of Halothane can be decreased when combined with Losartan.
LovastatinThe metabolism of Halothane can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Halothane.
Lu AA21004The risk or severity of adverse effects can be increased when Halothane is combined with Lu AA21004.
LuliconazoleThe serum concentration of Halothane can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Halothane can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Halothane can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Halothane is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Halothane.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Halothane is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Halothane is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Halothane is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Halothane is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Halothane.
MelperoneThe risk or severity of adverse effects can be increased when Halothane is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Halothane.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Halothane.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Halothane.
MetaxaloneThe risk or severity of adverse effects can be increased when Halothane is combined with Metaxalone.
MethadoneThe metabolism of Halothane can be decreased when combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Halothane is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Halothane is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Halothane is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Halothane is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Halothane is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Halothane.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Halothane is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Halothane.
MethsuximideThe risk or severity of adverse effects can be increased when Halothane is combined with Methsuximide.
MethylphenidateMethylphenidate may increase the hypertensive activities of Halothane.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Halothane.
MetoprololThe metabolism of Halothane can be decreased when combined with Metoprolol.
MetyrosineHalothane may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Halothane.
MifepristoneThe metabolism of Halothane can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Halothane is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Halothane.
MirabegronThe metabolism of Halothane can be decreased when combined with Mirabegron.
MirtazapineHalothane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Halothane.
MitotaneThe serum concentration of Halothane can be decreased when it is combined with Mitotane.
MivacuriumHalothane may increase the neuromuscular blocking activities of Mivacurium.
ModafinilThe serum concentration of Halothane can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Halothane is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Halothane.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Halothane.
NabiloneThe risk or severity of adverse effects can be increased when Halothane is combined with Nabilone.
NafcillinThe serum concentration of Halothane can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Halothane.
NefazodoneThe metabolism of Halothane can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Halothane can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Halothane can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Halothane can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Halothane can be decreased when combined with Nicardipine.
NicotineThe metabolism of Halothane can be decreased when combined with Nicotine.
NilotinibThe metabolism of Halothane can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Halothane is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Halothane is combined with Nitrous oxide.
NorepinephrineHalothane may increase the arrhythmogenic activities of Norepinephrine.
NormethadoneThe risk or severity of adverse effects can be increased when Halothane is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Halothane is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Halothane is combined with Olanzapine.
OlaparibThe metabolism of Halothane can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Halothane is combined with Olopatadine.
OmeprazoleThe metabolism of Halothane can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Halothane.
OpiumThe risk or severity of adverse effects can be increased when Halothane is combined with Opium.
OrphenadrineHalothane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Halothane.
OsanetantThe risk or severity of adverse effects can be increased when Halothane is combined with Osanetant.
OsimertinibThe serum concentration of Halothane can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Halothane.
OxprenololThe risk or severity of adverse effects can be increased when Halothane is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Halothane.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Halothane.
OxymorphoneThe risk or severity of adverse effects can be increased when Halothane is combined with Oxymorphone.
PalbociclibThe serum concentration of Halothane can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Halothane is combined with Paliperidone.
PanobinostatThe metabolism of Halothane can be decreased when combined with Panobinostat.
ParaldehydeHalothane may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Halothane.
ParoxetineThe risk or severity of adverse effects can be increased when Halothane is combined with Paroxetine.
ParoxetineThe metabolism of Halothane can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Halothane can be decreased when it is combined with Peginterferon alfa-2b.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Halothane.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Halothane.
PerampanelThe risk or severity of adverse effects can be increased when Halothane is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Halothane is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Halothane.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Halothane.
PhenobarbitalThe risk or severity of adverse effects can be increased when Halothane is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Halothane is combined with Phenoxyethanol.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Halothane.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Halothane.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Halothane.
PipamperoneThe risk or severity of adverse effects can be increased when Halothane is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Halothane is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Halothane is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Halothane is combined with Pomalidomide.
PosaconazoleThe metabolism of Halothane can be decreased when combined with Posaconazole.
PramipexoleHalothane may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Halothane is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Halothane is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Halothane.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Halothane.
PrimidoneThe risk or severity of adverse effects can be increased when Halothane is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Halothane.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Halothane.
PromazineThe metabolism of Halothane can be decreased when combined with Promazine.
PromazineThe risk or severity of adverse effects can be increased when Halothane is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Halothane is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Halothane.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Halothane.
PropoxycaineThe risk or severity of adverse effects can be increased when Halothane is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Halothane is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Halothane is combined with PSD502.
PyrimethamineThe metabolism of Halothane can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Halothane can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Halothane is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Halothane is combined with Quetiapine.
QuinidineThe metabolism of Halothane can be decreased when combined with Quinidine.
QuinineThe metabolism of Halothane can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Halothane is combined with Ramelteon.
RanolazineThe metabolism of Halothane can be decreased when combined with Ranolazine.
RapacuroniumHalothane may increase the neuromuscular blocking activities of Rapacuronium.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Halothane.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Halothane.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Halothane.
RifabutinThe metabolism of Halothane can be increased when combined with Rifabutin.
RifampicinThe metabolism of Halothane can be increased when combined with Rifampicin.
RifapentineThe metabolism of Halothane can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Halothane.
RitonavirThe metabolism of Halothane can be decreased when combined with Ritonavir.
RolapitantThe metabolism of Halothane can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Halothane is combined with Romifidine.
RopiniroleHalothane may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Halothane can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Halothane.
RotigotineHalothane may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Halothane.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Halothane is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Halothane can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Halothane is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Halothane.
SertindoleThe risk or severity of adverse effects can be increased when Halothane is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Halothane is combined with Sertraline.
SertralineThe metabolism of Halothane can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Halothane is combined with Sevoflurane.
SildenafilThe metabolism of Halothane can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Halothane can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Halothane can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Halothane is combined with Sodium oxybate.
SorafenibThe metabolism of Halothane can be decreased when combined with Sorafenib.
St. John's WortThe serum concentration of Halothane can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Halothane is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Halothane.
SulfadiazineThe metabolism of Halothane can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Halothane can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Halothane can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Halothane.
SuvorexantThe risk or severity of adverse effects can be increased when Halothane is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Halothane is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Halothane is combined with Tasimelteon.
TelaprevirThe metabolism of Halothane can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Halothane can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Halothane.
TerbinafineThe metabolism of Halothane can be decreased when combined with Terbinafine.
TetrabenazineThe risk or severity of adverse effects can be increased when Halothane is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Halothane is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Halothane is combined with Tetrodotoxin.
ThalidomideHalothane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Halothane.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Halothane.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Halothane.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Halothane.
ThiotepaThe metabolism of Halothane can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Halothane is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Halothane is combined with Tiagabine.
TicagrelorThe metabolism of Halothane can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Halothane can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Halothane is combined with Tiletamine.
TipranavirThe metabolism of Halothane can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Halothane is combined with Tizanidine.
TocilizumabThe serum concentration of Halothane can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Halothane can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Halothane is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Halothane is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Halothane.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Halothane is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe metabolism of Halothane can be decreased when combined with Tranylcypromine.
TranylcypromineThe risk or severity of adverse effects can be increased when Halothane is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Halothane is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Halothane.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Halothane.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Halothane.
TrimethoprimThe metabolism of Halothane can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Halothane is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Halothane is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Halothane.
ValsartanThe metabolism of Halothane can be decreased when combined with Valsartan.
VenlafaxineThe metabolism of Halothane can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Halothane can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Halothane is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Halothane is combined with Vilazodone.
VoriconazoleThe metabolism of Halothane can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Halothane is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Halothane is combined with Xylazine.
ZafirlukastThe metabolism of Halothane can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Halothane.
ZiconotideThe risk or severity of adverse effects can be increased when Halothane is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Halothane is combined with Zimelidine.
ZiprasidoneThe metabolism of Halothane can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Halothane is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Halothane is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Halothane.
ZonisamideThe risk or severity of adverse effects can be increased when Halothane is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Halothane is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Halothane is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Halothane is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
binder
General Function:
S100 protein binding
Specific Function:
pH-dependent, voltage-insensitive, background potassium channel protein. Rectification direction results from potassium ion concentration on either side of the membrane. Acts as an outward rectifier when external potassium concentration is low. When external potassium concentration is high, current is inward.
Gene Name:
KCNK3
Uniprot ID:
O14649
Molecular Weight:
43517.665 Da
References
  1. Lazarenko RM, Willcox SC, Shu S, Berg AP, Jevtovic-Todorovic V, Talley EM, Chen X, Bayliss DA: Motoneuronal TASK channels contribute to immobilizing effects of inhalational general anesthetics. J Neurosci. 2010 Jun 2;30(22):7691-704. doi: 10.1523/JNEUROSCI.1655-10.2010. [PubMed:20519544 ]
  2. Pandit JJ, Buckler KJ: Halothane and sevoflurane exert different degrees of inhibition on carotid body glomus cell intracellular Ca2+ response to hypoxia. Adv Exp Med Biol. 2010;669:201-4. doi: 10.1007/978-1-4419-5692-7_40. [PubMed:20217349 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
binder
General Function:
Voltage-gated potassium channel activity
Specific Function:
pH-dependent, voltage-insensitive, background potassium channel protein.
Gene Name:
KCNK9
Uniprot ID:
Q9NPC2
Molecular Weight:
42263.485 Da
References
  1. Lazarenko RM, Willcox SC, Shu S, Berg AP, Jevtovic-Todorovic V, Talley EM, Chen X, Bayliss DA: Motoneuronal TASK channels contribute to immobilizing effects of inhalational general anesthetics. J Neurosci. 2010 Jun 2;30(22):7691-704. doi: 10.1523/JNEUROSCI.1655-10.2010. [PubMed:20519544 ]
  2. Pandit JJ, Buckler KJ: Halothane and sevoflurane exert different degrees of inhibition on carotid body glomus cell intracellular Ca2+ response to hypoxia. Adv Exp Med Biol. 2010;669:201-4. doi: 10.1007/978-1-4419-5692-7_40. [PubMed:20217349 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activation dampens the excitatory events that elevate the cytosolic Ca(2+) concentration and/or depolarize the cell membrane. It therefore contributes to repolarization of the membrane potential. Plays a key ...
Gene Name:
KCNMA1
Uniprot ID:
Q12791
Molecular Weight:
137558.115 Da
References
  1. Namba T, Ishii TM, Ikeda M, Hisano T, Itoh T, Hirota K, Adelman JP, Fukuda K: Inhibition of the human intermediate conductance Ca(2+)-activated K(+) channel, hIK1, by volatile anesthetics. Eur J Pharmacol. 2000 Apr 28;395(2):95-101. [PubMed:10794813 ]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein phosphatase 2a binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism (By similarity).
Gene Name:
GRIN3A
Uniprot ID:
Q8TCU5
Molecular Weight:
125464.07 Da
References
  1. Perouansky M, Kirson ED, Yaari Y: Halothane blocks synaptic excitation of inhibitory interneurons. Anesthesiology. 1996 Dec;85(6):1431-8; discussion 29A. [PubMed:8968191 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Nmda glutamate receptor activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine.
Gene Name:
GRIN3B
Uniprot ID:
O60391
Molecular Weight:
112990.98 Da
References
  1. Perouansky M, Kirson ED, Yaari Y: Halothane blocks synaptic excitation of inhibitory interneurons. Anesthesiology. 1996 Dec;85(6):1431-8; discussion 29A. [PubMed:8968191 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels possesses high calcium permeability and voltage-dependent sensitivity to magnesium. Activation requires binding of agonist to both types of subunits.
Gene Name:
GRIN2A
Uniprot ID:
Q12879
Molecular Weight:
165281.215 Da
References
  1. Perouansky M, Kirson ED, Yaari Y: Halothane blocks synaptic excitation of inhibitory interneurons. Anesthesiology. 1996 Dec;85(6):1431-8; discussion 29A. [PubMed:8968191 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
allosteric modulator
General Function:
Transmitter-gated ion channel activity
Specific Function:
The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing).
Gene Name:
GLRA1
Uniprot ID:
P23415
Molecular Weight:
52623.35 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Schofield CM, Trudell JR, Harrison NL: Alanine-scanning mutagenesis in the signature disulfide loop of the glycine receptor alpha 1 subunit: critical residues for activation and modulation. Biochemistry. 2004 Aug 10;43(31):10058-63. [PubMed:15287733 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Photoreceptor activity
Specific Function:
Photoreceptor required for image-forming vision at low light intensity. Required for photoreceptor cell viability after birth. Light-induced isomerization of 11-cis to all-trans retinal triggers a conformational change leading to G-protein activation and release of all-trans retinal.
Gene Name:
RHO
Uniprot ID:
P08100
Molecular Weight:
38892.335 Da
References
  1. Ishizawa Y, Sharp R, Liebman PA, Eckenhoff RG: Halothane binding to a G protein coupled receptor in retinal membranes by photoaffinity labeling. Biochemistry. 2000 Jul 25;39(29):8497-502. [PubMed:10913255 ]
  2. Keller C, Grimm C, Wenzel A, Hafezi F, Reme C: Protective effect of halothane anesthesia on retinal light damage: inhibition of metabolic rhodopsin regeneration. Invest Ophthalmol Vis Sci. 2001 Feb;42(2):476-80. [PubMed:11157886 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Inward rectifier potassium channel activity
Specific Function:
This potassium channel may be involved in the regulation of insulin secretion by glucose and/or neurotransmitters acting through G-protein-coupled receptors. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external ...
Gene Name:
KCNJ6
Uniprot ID:
P48051
Molecular Weight:
48450.96 Da
References
  1. Milovic S, Steinecker-Frohnwieser B, Schreibmayer W, Weigl LG: The sensitivity of G protein-activated K+ channels toward halothane is essentially determined by the C terminus. J Biol Chem. 2004 Aug 13;279(33):34240-9. Epub 2004 Jun 2. [PubMed:15175324 ]
  2. Hara K, Yamakura T, Sata T, Harris RA: The effects of anesthetics and ethanol on alpha2 adrenoceptor subtypes expressed with G protein-coupled inwardly rectifying potassium channels in Xenopus oocytes. Anesth Analg. 2005 Nov;101(5):1381-8. [PubMed:16243998 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
G-protein activated inward rectifier potassium channel activity
Specific Function:
This potassium channel is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward...
Gene Name:
KCNJ3
Uniprot ID:
P48549
Molecular Weight:
56602.84 Da
References
  1. Weigl LG, Schreibmayer W: G protein-gated inwardly rectifying potassium channels are targets for volatile anesthetics. Mol Pharmacol. 2001 Aug;60(2):282-9. [PubMed:11455015 ]
  2. Yamakura T, Lewohl JM, Harris RA: Differential effects of general anesthetics on G protein-coupled inwardly rectifying and other potassium channels. Anesthesiology. 2001 Jul;95(1):144-53. [PubMed:11465552 ]
  3. Milovic S, Steinecker-Frohnwieser B, Schreibmayer W, Weigl LG: The sensitivity of G protein-activated K+ channels toward halothane is essentially determined by the C terminus. J Biol Chem. 2004 Aug 13;279(33):34240-9. Epub 2004 Jun 2. [PubMed:15175324 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Nadh dehydrogenase (ubiquinone) activity
Specific Function:
Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).
Gene Name:
MT-ND1
Uniprot ID:
P03886
Molecular Weight:
35660.055 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Hanley PJ, Ray J, Brandt U, Daut J: Halothane, isoflurane and sevoflurane inhibit NADH:ubiquinone oxidoreductase (complex I) of cardiac mitochondria. J Physiol. 2002 Nov 1;544(Pt 3):687-93. [PubMed:12411515 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein phosphatase binding
Specific Function:
Forms a voltage-independent potassium channel that is activated by intracellular calcium (PubMed:26148990). Activation is followed by membrane hyperpolarization which promotes calcium influx. Required for maximal calcium influx and proliferation during the reactivation of naive T-cells. The channel is blocked by clotrimazole and charybdotoxin but is insensitive to apamin (PubMed:17157250, PubMe...
Gene Name:
KCNN4
Uniprot ID:
O15554
Molecular Weight:
47695.12 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Namba T, Ishii TM, Ikeda M, Hisano T, Itoh T, Hirota K, Adelman JP, Fukuda K: Inhibition of the human intermediate conductance Ca(2+)-activated K(+) channel, hIK1, by volatile anesthetics. Eur J Pharmacol. 2000 Apr 28;395(2):95-101. [PubMed:10794813 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Transporter activity
Specific Function:
Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain. F-type ATPases consist of two structural domains, F(1) - containing the extramembraneous catalytic core, and F(0) - containing the membrane proton channel, linked toget...
Gene Name:
ATP5D
Uniprot ID:
P30049
Molecular Weight:
17489.755 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Signal transducer activity
Specific Function:
This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the transport of the calcium.
Gene Name:
ATP2C1
Uniprot ID:
P98194
Molecular Weight:
100576.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Signal transducer activity
Specific Function:
Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction (By similarity).
Gene Name:
GNG2
Uniprot ID:
P59768
Molecular Weight:
7850.03 Da
References
  1. Ishizawa Y, Sharp R, Liebman PA, Eckenhoff RG: Halothane binding to a G protein coupled receptor in retinal membranes by photoaffinity labeling. Biochemistry. 2000 Jul 25;39(29):8497-502. [PubMed:10913255 ]
  2. Zang WJ, Yu XJ, Zang YM: [Effect of halothane on the muscarinic potassium current of the heart]. Sheng Li Xue Bao. 2000 Apr;52(2):175-8. [PubMed:11961592 ]
  3. Yoshimura H, Jones KA, Perkins WJ, Warner DO: Dual effects of hexanol and halothane on the regulation of calcium sensitivity in airway smooth muscle. Anesthesiology. 2003 Apr;98(4):871-80. [PubMed:12657848 ]
  4. Streiff J, Jones K, Perkins WJ, Warner DO, Jones KA: Effect of halothane on the guanosine 5' triphosphate binding activity of G-protein alphai subunits. Anesthesiology. 2003 Jul;99(1):105-11. [PubMed:12826849 ]
  5. Milovic S, Steinecker-Frohnwieser B, Schreibmayer W, Weigl LG: The sensitivity of G protein-activated K+ channels toward halothane is essentially determined by the C terminus. J Biol Chem. 2004 Aug 13;279(33):34240-9. Epub 2004 Jun 2. [PubMed:15175324 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Vasopressin receptor activity
Specific Function:
G-protein coupled receptor for neuropeptide S (NPS) (PubMed:16790440). Promotes mobilization of intracellular Ca(2+) stores (PubMed:16790440). Inhibits cell growth in response to NPS binding (PubMed:15947423). Involved in pathogenesis of asthma and other IgE-mediated diseases.
Gene Name:
NPSR1
Uniprot ID:
Q6W5P4
Molecular Weight:
42686.28 Da
References
  1. Ishizawa Y, Sharp R, Liebman PA, Eckenhoff RG: Halothane binding to a G protein coupled receptor in retinal membranes by photoaffinity labeling. Biochemistry. 2000 Jul 25;39(29):8497-502. [PubMed:10913255 ]
  2. Ishizawa Y, Pidikiti R, Liebman PA, Eckenhoff RG: G protein-coupled receptors as direct targets of inhaled anesthetics. Mol Pharmacol. 2002 May;61(5):945-52. [PubMed:11961111 ]
  3. Streiff J, Jones K, Perkins WJ, Warner DO, Jones KA: Effect of halothane on the guanosine 5' triphosphate binding activity of G-protein alphai subunits. Anesthesiology. 2003 Jul;99(1):105-11. [PubMed:12826849 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Restrepo JG, Garcia-Martin E, Martinez C, Agundez JA: Polymorphic drug metabolism in anaesthesia. Curr Drug Metab. 2009 Mar;10(3):236-46. [PubMed:19442086 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Spracklin DK, Hankins DC, Fisher JM, Thummel KE, Kharasch ED: Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. J Pharmacol Exp Ther. 1997 Apr;281(1):400-11. [PubMed:9103523 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Restrepo JG, Garcia-Martin E, Martinez C, Agundez JA: Polymorphic drug metabolism in anaesthesia. Curr Drug Metab. 2009 Mar;10(3):236-46. [PubMed:19442086 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Restrepo JG, Garcia-Martin E, Martinez C, Agundez JA: Polymorphic drug metabolism in anaesthesia. Curr Drug Metab. 2009 Mar;10(3):236-46. [PubMed:19442086 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Sawas AH, Pentyala SN, Rebecchi MJ: Binding of volatile anesthetics to serum albumin: measurements of enthalpy and solvent contributions. Biochemistry. 2004 Oct 5;43(39):12675-85. [PubMed:15449957 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23